The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Open accessThe DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While most HDACi tend to employ a hydroxamic acid as a ZBG, class I HDACs (particularly HDACs 1–3) tend to be the only class of HDACs inhibited by 2-amino anilides as a ZBG (Figure 4A) [9–13].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · cited 4×
“Many HDAC inhibitors have been developed, including four U.S. Food and Drug Administration (FDA) approved anticancer drugs; vorinostat (SAHA) [50], belinostat [51], panobinostat [52], and Molecules 2018, 23, 551 4 of 13 romidepsin [53] (Figure 2).”
BackgroundInfluentialThe Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
The impact of cellular metabolism on chromatin dynamics and epigenetics
Reid, M. A., Dai, Z., & Locasale, J. W. (2017) · Nature Cell Biology · doi:10.1038/ncb3629 · Cited by 515
Enhanced Histone Acetylation and Transcription: A Dynamic Perspective
Clayton, A. L., Hazzalin, C. A., & Mahadevan, L. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.017 · Cited by 473
Vigushin, D. M., Ali, S., Pace, P., Mirsaidi, N., Ito, K., Adcock, I. M., & Coombes, R. C. (2001) · PubMed · Cited by 447
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Lee, H.-Z., Kwitkowski, V. E., Del Valle, P. L., Ricci, M. S., Saber, H., Habtemariam, B. A., Bullock, J., Bloomquist, E., Li Shen, Y., Chen, X.-H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3119 · Cited by 357
Expression profile of class I histone deacetylases in human cancer tissues
Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., et al. (2007) · Oncology Reports · doi:10.3892/or.18.4.769 · Cited by 341
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332
Hull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 313
Inside HDACs with more selective HDAC inhibitors
Roche, J., & Bertrand, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.047 · Cited by 312
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides
Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., Jong, R. D., O’Connell, S., Grimshaw, C. E., Navre, M., & Gangloff, A. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.091 · Cited by 261 · cited 2×
“In contrast to the serines in HDAC 1 and 2, the tyrosine 107 in HDAC3 provides steric hindrance for binding to the foot pocket, thus precluding binding of inhibitors with larger functional groups in this position [25,26].”
BackgroundReuse, S., Calao, M., Kabeya, K., Guiguen, A., Gatot, J.-S., Quivy, V., Vanhulle, C., Lamine, A., Vaira, D., Demonte, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006093 · Cited by 240
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223 · cited 4×
“This compound has a Ki value of 14 nM for HDAC3, which w s 10 times lower than the i for HDAC1 [55,56], while its analog, RGFP109, which is lso used as a promising treatment for Friedreich’s ataxia, show better potency for HDAC3 with the Ki value of 5 nM, nd 32 nM for HDAC1 [57].”
BackgroundInfluentialKwon, H. J., Owa, T., Hassig, C. A., Shimada, J., & Schreiber, S. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3356 · Cited by 197
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191 · cited 1×
“Most notably, the tyrosine in position 107 in HDAC 3 is a serine in HDAC 1 and 2, which is a difference that has been used to rationalize the identification of HDAC1/2 selective inhibitors [24].”
BackgroundTargeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180 · cited 1×
“A structural alignment of HDAC3 with HDAC1 and 2 reveals five differences [22,23], shown in Table 1.”
BackgroundWhitehead, L., Dobler, M. R., Radetich, B., Zhu, Y., Atadja, P. W., Claiborne, T., Grob, J. E., McRiner, A., Pancost, M. R., Patnaik, A., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.030 · Cited by 164
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159
Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma.
Louder, A. M., Singh, A., Saverno, K. R., Cappelleri, J. C., Aten, A. J., Koenig, A. S., & Pasquale, M. K. (2016) · Europe PMC (PubMed Central) · Cited by 155
Ahmad Ganai, S., Ramadoss, M., & Mahadevan, V. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151021111609 · Cited by 152
Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation
Leus, N. G., Zwinderman, M. R., & Dekker, F. J. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.019 · Cited by 150
Self-citationRai, M., Soragni, E., Chou, C. J., Barnes, G., Jones, S., Rusche, J. R., Gottesfeld, J. M., & Pandolfo, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008825 · Cited by 144
Dekker, F. J., van den Bosch, T., & Martin, N. I. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.012 · Cited by 132
Self-citationLeus, N. G. J., van der Wouden, P. E., van den Bosch, T., Hooghiemstra, W. T. R., Ourailidou, M. E., Kistemaker, L. E. M., Bischoff, R., Gosens, R., Haisma, H. J., & Dekker, F. J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.03.010 · Cited by 131 · cited 2×
“In precision-cut lung slices (PCLS), a selective HDAC3 inhibitor is shown to increase the expression of IL-10, an important anti-inflammatory cytokine, and decrease the gene expression of pro-inflammatory cytokines by attenuating NF-κB p65 transcriptional activity [48].”
BackgroundSelf-citationExpression and Function of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts
HORIUCHI, M., MORINOBU, A., CHIN, T., SAKAI, Y., KUROSAKA, M., & KUMAGAI, S. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081115 · Cited by 114
HDAC 3 negatively regulates spatial memory in a mouse model of Alzheimer's disease
Zhu, X., Wang, S., Yu, L., Jin, J., Ye, X., Liu, Y., & Xu, Y. (2017) · Aging Cell · doi:10.1111/acel.12642 · Cited by 112 · cited 1×
“HDAC3, in particular, is an interesting target in Alzheimer’s disease [31,46], since it is reported that HDAC3 plays an important role in maintaining long-term memory for object location [47].”
BackgroundSelective histone deacetylase small molecule inhibitors: recent progress and perspectives
Qin, H., Li, H., & Liu, F. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1276565 · Cited by 105
Suzuki, T., Kasuya, Y., Itoh, Y., Ota, Y., Zhan, P., Asamitsu, K., Nakagawa, H., Okamoto, T., & Miyata, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068669 · Cited by 101
Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats
Lundh, M., Galbo, T., Poulsen, S. S., & Mandrup‐Poulsen, T. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12470 · Cited by 100
Jia, H., Wang, Y., Morris, C. D., Jacques, V., Gottesfeld, J. M., Rusche, J. R., & Thomas, E. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152498 · Cited by 94
Wagner, F. F., Lundh, M., Kaya, T., McCarren, P., Zhang, Y.-L., Chattopadhyay, S., Gale, J. P., Galbo, T., Fisher, S. L., Meier, B. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00640 · Cited by 86 · cited 5×
“15 μM for HDAC1 and 2, respectively [22].”
BackgroundInfluentialHistone deacetylases in viral infections
Herbein, G., & Wendling, D. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0003-5 · Cited by 82
Suelves, N., Kirkham-McCarthy, L., Lahue, R. S., & Ginés, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-05125-2 · Cited by 79
Wagner, F. F., Weïwer, M., Steinbacher, S., Schomburg, A., Reinemer, P., Gale, J. P., Campbell, A. J., Fisher, S. L., Zhao, W., Reis, S. A., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.040 · Cited by 79
Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection
Barton, K. M., Archin, N. M., Keedy, K. S., Espeseth, A. S., Zhang, Y.-L., Gale, J., Wagner, F. F., Holson, E. B., & Margolis, D. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102684 · Cited by 76 · cited 2×
“This compound also shows potency for the therapy of HIV infection [40] and diabetes [43,45].”
BackgroundLeus, N. G. J., van den Bosch, T., van der Wouden, P. E., Krist, K., Ourailidou, M. E., Eleftheriadis, N., Kistemaker, L. E. M., Bos, S., Gjaltema, R. A. F., Mekonnen, S. A., et al. (2017) · Scientific Reports · doi:10.1038/srep45047 · Cited by 76
Self-citationInnovative Strategies for Selective Inhibition of Histone Deacetylases
Maolanon, A. R., Madsen, A. S., & Olsen, C. A. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.011 · Cited by 72
3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition
Patil, V., Sodji, Q. H., Kornacki, J. R., Mrksich, M., & Oyelere, A. K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301769u · Cited by 72
Sato, N., Ohta, T., Kitagawa, H., Kayahara, M., Ninomiya, I., Fushida, S., Fujimura, T., Nishimura, G., Shimizu, K., & Miwa, K. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.3.679 · Cited by 71
Targeting breast cancer stem cells by novel HDAC3-selective inhibitors
Hsieh, H.-Y., Chuang, H.-C., Shen, F.-H., Detroja, K., Hsin, L.-W., & Chen, C.-S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.069 · Cited by 67
Cyrenne, B. M., Lewis, J. M., Weed, J. G., Carlson, K. R., Mirza, F. N., Foss, F. M., & Girardi, M. (2017) · Blood · doi:10.1182/blood-2017-06-792150 · Cited by 64
Marson, C. M., Matthews, C. J., Yiannaki, E., Atkinson, S. J., Soden, P. E., Shukla, L., Lamadema, N., & Thomas, N. S. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400634n · Cited by 54
HDACis (class I), cancer stem cell, and phytochemicals: Cancer therapy and prevention implications
Bayat, S., Khaniani, M. S., Choupani, J., Alivand, M. R., & Derakhshan, S. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.065 · Cited by 54
HIV-1 Vpr reactivates latent HIV-1 provirus by inducing depletion of class I HDACs on chromatin
Romani, B., Jamil, R. K., Hamidi-Fard, M., Rahimi, P., Momen, S. B., Aghasadeghi, M. R., & Allahbakhshi, E. (2016) · Scientific Reports · doi:10.1038/srep31924 · Cited by 52
Park, H., Kim, S., Kim, Y. E., & Lim, S. (2010) · ChemMedChem · doi:10.1002/cmdc.200900500 · Cited by 52
Chen, Y., He, R., Chen, Y., D'Annibale, M. A., Langley, B., & Kozikowski, A. P. (2009) · ChemMedChem · doi:10.1002/cmdc.200800461 · Cited by 51
The Class I HDAC inhibitor RGFP963 enhances consolidation of cued fear extinction
Bowers, M. E., Xia, B., Carreiro, S., & Ressler, K. J. (2015) · Learning & Memory · doi:10.1101/lm.036699.114 · Cited by 50
Comparison of the Deacylase and Deacetylase Activity of Zinc-Dependent HDACs
McClure, J. J., Inks, E. S., Zhang, C., Peterson, Y. K., Li, J., Chundru, K., Lee, B., Buchanan, A., Miao, S., & Chou, C. J. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00321 · Cited by 49
Dirice, E., Ng, R. W. S., Martinez, R., Hu, J., Wagner, F. F., Holson, E. B., Wagner, B. K., & Kulkarni, R. N. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.804328 · Cited by 49
Soragni, E., Xu, C., Plasterer, H. L., Jacques, V., Rusche, J. R., & Gottesfeld, J. M. (2012) · Journal of Child Neurology · doi:10.1177/0883073812448533 · Cited by 36
Inhibition of Hdac3 as a Strategy for Developing Novel Diabetes Therapeutics
Meier, B. C., & Wagner, B. K. (2014) · Epigenomics · doi:10.2217/epi.14.11 · Cited by 34
Alaghband, Y., Kwapis, J. L., López, A. J., White, A. O., Aimiuwu, O. V., Al-Kachak, A., Bodinayake, K. K., Oparaugo, N. C., Dang, R., Astarabadi, M., et al. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.09.001 · Cited by 34 · cited 1×
“HDAC3, in particular, is an interesting target in Alzheimer’s disease [31,46], since it is reported that HDAC3 plays an important role in maintaining long-term memory for object location [47].”
BackgroundSymanowski, J. T., Vogelzang, N. J., Zawel, L. S., Atadja, P. W., Pass, H. I., & Sharma, S. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318194f991 · Cited by 31
A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold
Kemp, M. M., Wang, Q., Fuller, J. H., West, N. H., Martínez, N. M., Morse, E. M., Weïwer, M., Schreiber, S. L., Bradner, J. E., & Koehler, A. N. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.05.098 · Cited by 24
Design and synthesis of novel hybrid benzamide–peptide histone deacetylase inhibitors
Hu, F., Chou, C. J., & Gottesfeld, J. M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.085 · Cited by 24
Dihydrocoumarin, an HDAC Inhibitor, Increases DNA Damage Sensitivity by Inhibiting Rad52
Chen, C., Huang, J.-S., Wang, T., Kuo, C.-H., Wang, C.-J., Wang, S., & Leu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122655 · Cited by 24
Depletion of Histone Deacetylase I Protein: A Common Consequence of Inflammatory Cytokine Signaling?
Gopal, Y. N. V., & Dyke, M. W. V. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3522 · Cited by 19
Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis
Zhang, M., Yin, Y., Dorfman, R. G., Zou, T., Pan, Y., Li, Y., Wang, Y., Zhou, Q., Zhou, L., Kong, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19660 · Cited by 18
Sun, X.-Y., Qu, Y., Ni, A.-R., Wang, G.-X., Huang, W.-B., Chen, Z., Lv, Z., Zhang, S., Lindsay, H., Zhao, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20744 · Cited by 15
Dolskiy, A. A., Pustylnyak, V. O., Yarushkin, A. A., Lemskaya, N. A., & Yudkin, D. V. (2017) · BioMed Research International · doi:10.1155/2017/3582601 · Cited by 14
Wapenaar, H., van den Bosch, T., Leus, N. G. J., van der Wouden, P. E., Eleftheriadis, N., Hermans, J. H., Hailu, G. S., Rotili, D., Mai, A., Dömling, A. S. S., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.015 · Cited by 12
Self-citationOurailidou, M. E., Leus, N. G. J., Krist, K., Lenoci, A., Mai, A., & Dekker, F. J. (2016) · MedChemComm · doi:10.1039/c6md00375c · Cited by 10
Self-citationWu, Y., Quan, Y., Zhang, D. X., Liu, D. W., & Zhang, X. Z. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00360 · Cited by 8
Opening the genome to reduce cocaine-seeking behavior
LaLumiere, R. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222128110 · Cited by 1
Cited by
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Lanka, G., Begum, D., Banerjee, S., Adhikari, N., Yogeeswari, P., & Ghosh, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107481 · Cited by 112
Smalley, J. P., Baker, I. M., Pytel, W. A., Lin, L., Bowman, K. J., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02179 · Cited by 85
Kaliman, P. (2018) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2018.11.010 · Cited by 97
Metadata
- Authors
- Cao, F., Zwinderman, M., & Dekker, F.
- Affiliations
- University of Groningen (NL)
- Corresponding author
- Dekker, Frank
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2018-03-02
- Volume
- 23
- Issue
- 3
- Pages
- 551
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6017514
- OpenAlex
- W2791709427
- Cited by
- 66
- References
- 71
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 6 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 4 · 2019: 6 · 2018: 4
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- ERC (309782)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (723.012.005)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- HDAC3, HDAC3 inhibitors, selective inhibitors, epigenetic drug targets, cancer therapy, inflammation, neurodegenerative diseases
- MeSH terms
- Vorinostat, Panobinostat, Histone Deacetylase 3, Antineoplastic Agents, Histone Deacetylases, Humans, Hydroxamic Acids, Indoles, Inflammation, Isoenzymes, Neoplasm Proteins, Neoplasms, Structure-Activity Relationship, Sulfonamides, Drug Design, Neurodegenerative Diseases, Epigenesis, Genetic, Depsipeptides, Histone Deacetylase Inhibitors, Chemistry Techniques, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.